| *Sponsored by Sica Media | Good morning, Folks — Jeff Bishop here again. | The markets continue to defy the skeptics, and power higher seemingly every day lately. | I pity those on the short side of trades. It has been a bloodbath for the bears. | With the intense short-covering we have seen in the broad market lately, there are very few stocks I am interested in at current prices. | I'd much rather look at stocks that have shown a lot of strength in the last few months, but have cooled off a bit recently. That is where I think the future big moves will come from. | As I have been looking at charts this week, there is one that stands out that I think you need to pull up immediately… | MAIA Biotechnology, Inc. (NYSE: MAIA) | I brought this stock to your attention about a month ago, and it made a great move, if you were watching it then. | Now I'm seeing some very similar patterns appear again. | If you look at the chart below, you'll see that we are seeing multiple "GO" signals once again and the stock has been building a base around $1.80. | | If you look at this chart, you can almost "feel" the coiling action happening now, right? | When MAIA decides to break out of this range, I think it could be really explosive. | And why wouldn't it? | The market is en fuego 🔥 lately and MAIA keeps delivering strong news, is led by excellent leadership that has shown their support by actively making stock purchases (as well as an announcing stock buyback program), and analyst coverage is forecasting a massive upside target from current prices. | First, let me go over the recent news. MAIA has been a NEWS MACHINE lately. This is exactly what I would expect to see from a stock that makes it on my radar. | There is so much happening lately, I couldn't list it all, but I summarized the best I could. I also added the link to the news so you can go read it for yourself. | This is some truly amazing stuff! | | October 24: | "MAIA Biotechnology, Inc. reported positive preliminary efficacy data from its ongoing Phase 2 clinical trial, THIO-101, evaluating THIO in patients with advanced Non-Small Cell Lung Cancer (NSCLC) in sequential combination with Regeneron's anti-PD-1 cemiplimab (Libtayo). Key findings: 100% Preliminary DCR observed in second-line and 88% in third-line, in highly difficult-to-treat patients who already progressed through previous lines of treatment. DCRs across all dose levels met the pre-determined statistical requirements earlier than expected to proceed to [the] next stage of the trial." [emphases added] | November 7: | Great financial numbers released. "Basic loss per share from continuing operations was $.36 compared to $.48 a year ago." Substantial improvement. | November 7: | "Preliminary efficacy data from the trial is excellent and includes an unprecedented disease control rate (DCR) of 100% in second-line NSCLC treatment, far surpassing the standard of care DCR of 53-64%. We achieved the predetermined statistical requirements to proceed to the next stage of the trial earlier than expected, and we look forward to sharing our continuing progress in the coming months and into 2024." [emphasis added] | November 10: | "MAIA Biotechnology has won a THIRD FDA granted orphan-drug designation for THIO, the clinical-stage biopharmaceutical company's lead asset. | The Chicago company on Friday said the latest designation covers THIO for the treatment of glioblastoma, the most aggressive type of brain tumor. | The FDA's orphan-drug program gives special status to drugs and biologics for diseases and disorders that affect fewer than 200,000 people in the U.S. and provides for an extended marketing exclusivity period against competition. | The FDA last year granted orphan-drug designation to THIO in hepatocellular carcinoma and small-cell lung cancer." [emphasis added] | November 9: | From an interview with MAIA's CEO: | "Late last month, MAIA Biotechnology reported a 100% Disease Control Rate in second-line treatment for NSCLC in its ongoing phase 2 trial, THIO-101. The preliminary efficacy data is 'promising given that the number surpasses the standard-of-care DCR, which ranges from 53% to 64%,' the company said. Additionally, 88% DCR was achieved in third-line treatments in the trial, far exceeding the approximate 30% DCR reported in existing studies. The ongoing THIO-101 Phase 2 clinical trial has two primary objectives, namely to evaluate safety and assess clinical efficacy using Overall Response Rate as the primary clinical endpoint. 'We presented data of the highest quality. I've never seen numbers like this. With a standard of care therapy, in first line of therapy, disease control rates are 70%, in second are 50%, and in third they're 30,' the executive added. | Aside from the trial in NSCLC, the company has two additional THIO trials planned. One of those is in colorectal, HCC, small cell lung cancer, while the other is a confirmatory/definitive approval basket study. 'We have two trials planned and in fact, we'll have an additional one designed soon. There will be three trials soon. The drug THIO has a very broad spectrum of activity. So, we developed data in several tumor types, preclinically. Lung is one, but also liver -- extraordinary data in liver cancer, which is very difficult to treat --, brain cancer, small cell lung cancer, and colorectal cancer. We are planning to develop THIO in this indication as well,' Vitoc explained." [emphases added] | November 10: | "In the data presented to the FDA, THIO successfully penetrated the blood brain barrier (BBB) in syngeneic and humanized mouse models of telomerase-expressing brain cancers. Treatment with THIO resulted in potent anticancer activity and significant expansion of the animal lifespan for several difficult to treat cell lines and xenograft mouse models," added Sergei Gryaznov, Ph.D., MAIA's Chief Scientific Officer. "These results stem from THIO's remarkable mechanism of action and its BBB penetrating property that allows for direct targeting of brain tumors in vivo and potentially in glioblastoma patients." [emphasis added] | | 👉 I mean, after reading this you have to agree that MAIA is really on the cusp of something big… right??? | This is NOT the type of news you find from most small biotech companies. | Improving financials… FDA "Orphan Drug" designation... "Fast Track" clearance... Positive drug trials. | Considering the price it is trading at right now, MAIA could be sitting on some of the biggest potential biomed assets I have ever seen, and the story is unfolding right before our eyes. | Insider Confidence Is High | One of the biggest things to look for when surveying a clinical-stage biotech is positive insider sentiment. | Obviously these companies will put on a smile in their press releases and corporate presentations, but when it comes down to it, will they put their own money where their mouths are? | Well clearly, the top folks at MAIA are true believers: | | Over the last year, company insiders bought shares 79 times and didn't have a single sell reported, even during the post-January drawdown. | MAIA insiders are actually putting more skin in the game with shareholders. | This tells me the people who would know best believe in the efficacy of their drug pipeline and believe that at least some products will pan out. | Another very strong sign of insider confidence was the announcement of an $800,000 share repurchase program that the company can exercise through September 2024. | $800k is nothing to sneeze at for a company with a smaller market cap like MAIA! | But more important than what the program could do to the share price is that it signals MAIA isn't likely to do a capital raise right now (at least in my humble opinion), and that executives feel comfortable enough with their cash reserves that they are choosing to add value to shareholders by purchasing their own stock. | Again, all of this tells me that the "people who would know" see a bright future 😎 for MAIA. | Bullish Sentiment Abounds | But MAIA executives aren't the only ones who seem bullish on the stock. | In my last write up about MAIA, I quoted the incredibly-named Biotech Beast of Seeking Alpha who considered the company a "buy" in July. In the same article, he outlined his reservations: | The risks of any long in MAIA are several fold . . . . Firstly, subsequent data from THIO-101 could disappoint, secondly, MAIA could fail to raise additional funds leading to concerns over cash and thirdly, delays in enrollment could cause the stock to trade down. | With the benefit of hindsight, I think we can say all those concerns have been mitigated at the very least. | While Mr. Beast's analysis didn't make it to TipRanks, I was able to find that an analyst from Noble Financial reiterated a "buy" rating with a whopping $14.00 price target for MAIA — which would make it more than a "six-bagger" opportunity from its current price of less than $2 a share. | Clearly, people who know a lot more about MAIA than I do are super excited about this opportunity – so you need to do your homework on this right away. | I think now is a critical time to take a look at this stock. | The news about the success of the company's leading asset is hot off the presses, and investors are just coming to terms with it. | Clearly, investors see promise in MAIA's potentially groundbreaking therapeutics, and this latest batch of news will only help confirm that. | I think the recent rallies for the stock that we have seen could likely be in the early innings of something much bigger 🚀. | Judging by the price action, I think there is a big move coming for MAIA (one way or another) very soon – be on the lookout for it! | That's what I think. As always, you must do your own research to see if you agree. Google "MAIA", study the chart, read the financials… do all your due diligence and have a gameplan that fits your personal risk profile. | But do so soon, because I think this one could be ready to explode 🧨. | To Your Success, | | *This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results. | | DISCLAIMER | *PAID ADVERTISEMENT. Raging Bull has currently been paid fourteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc from a period beginning on November 15 through November 18, 2023. Raging Bull has previously been paid fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc from a period beginning on October 12 through October 13, 2023. The third party, Company, or their affiliates may own and likely wish to liquidate shares of the Company at or near the time you receive this advertisement, which has the potential to hurt share prices. This advertisement and other marketing efforts, including alerts, may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of MAIA Biotechnology, Inc, increased trading volume, and possibly an increased share price of MAIA Biotechnology, Inc's securities, which may or may not be temporary and decrease once the marketing arrangement has ended. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of the issuance of this advertisement, the owners of Raging Bull do not hold a position in MAIA Biotechnology, Inc, though they reserve the right to buy or sell shares in the covered company at any time following the dissemination of this communication. | FOR COMMERCIAL AND INFORMATIONAL PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for commercial and informational purposes only. A portion of our business is engaged in the promotion, marketing, and advertising of companies including public companies. A portion of Raging Bull's business model is to receive financial compensation to promote public companies, conduct investor relations advertising and marketing, and publicly disseminate information regarding public companies through our websites email, SMS, and push notifications among other methods of communication. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. All material information contained in this advertisement is based on information generally available to the public, including information released to the public or filed by the Company with applicable regulators which public information is believed to be reliable and accurate. Nevertheless, Raging Bull cannot guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company's financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision. | SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. Never invest in any stock featured in this advertisement, on our site or emails unless you can afford to lose your entire investment. | NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. | USE OF FORWARD-LOOKING STATEMENTS. Our advertisements including this advertisement and related emails, reports and alerts may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information in this advertisement, related emails, reports or alerts or on our website or media webpage. This information is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as "believes," "anticipates," "estimates," "expects," "projects," "intends," or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https:// www .sec .gov/edgar/searchedgar/company search | TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied. | WE MAY HOLD SECURITIES DISCUSSED. Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. |
|
| |
|
Post a Comment
Post a Comment